Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22

This study has been completed.
National Institute on Drug Abuse (NIDA)
Information provided by:
University of Vermont Identifier:
First received: September 20, 1999
Last updated: June 2, 2015
Last verified: April 1999
The purpose of this study is to test combined buprenorphine and behavioral treatment with and without contingent reinforcement on opioid and cocaine abstinence.

Condition Intervention Phase
Cocaine-Related Disorders
Opioid-Related Disorders
Drug: Buprenorphine
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Combined Buprenorphine and Behavioral Treatment Without Contingent Reinforcement

Resource links provided by NLM:

Further study details as provided by University of Vermont:

Primary Outcome Measures:
  • Drug use
  • Retention
  • Weeks abstinent
  • Weeks continuous abstinence
  • Overall treatment outcome
  • Opioid dependence and psychiatric status

Estimated Enrollment: 0
Study Start Date: April 1999

Ages Eligible for Study:   23 Years to 47 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000240

United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
University of Vermont
National Institute on Drug Abuse (NIDA)
Principal Investigator: Warren Bickel, Ph.D. University of Vermont
  More Information

No publications provided Identifier: NCT00000240     History of Changes
Other Study ID Numbers: NIDA-06969-22, R01DA006969, R01-06969-22
Study First Received: September 20, 1999
Last Updated: June 2, 2015
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Opioid-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Pathologic Processes
Substance-Related Disorders
Analgesics, Opioid
Central Nervous System Agents
Central Nervous System Depressants
Narcotic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 27, 2015